The ability of A661 and A665 to block growth of B-cell lymphomas from multiple independent patients as well as leukemogenesis in a preclinical model point to their potential application as drugs for the treatment of leukemias and other cancers driven by Fli-1 overexpression. Here, FLI1 is linked to leukemia.